Insights

Market Access

Logan Pharmaceuticals insights on Market Access.

Unbranded inhalers and medicine packs arranged for sustainability planning

21 Jul 2026 Logan Pharmaceuticals

Lower-carbon inhalers in the UK: why the 2026 MHRA approval matters

MHRA's July 2026 approval of lower-carbon beclometasone inhalers shows how medicine innovation now joins clinical, regulatory and sustainability planning.

Read article

Market Access Pharmaceutical industry Sustainability

Pharmaceutical pricing documents and neutral medicine packs

10 Jun 2026 Logan Pharmaceuticals

Branded medicines pricing 2026: statutory scheme changes and supply-chain planning

DHSC's 2026 statutory scheme update resets branded medicines payment percentages. We summarise the market-access signals for suppliers.

Read article

Market Access Pharmaceutical industry Pricing

Medicine launch planning documents with regulatory timeline

9 Apr 2026 Logan Pharmaceuticals

MHRA-NICE aligned pathway 2026: what faster medicine access means for market planning

The 2026 MHRA-NICE aligned pathway brings licensing and NICE appraisal milestones closer together. Here is what supply partners should prepare for.

Read article

Market Access Pharmaceutical industry Regulation